Jutta Huvila

Potential targets analysis reveals pi3k/mtor pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas (2016)

International Journal of Gynecological Cancer

Cuppens T, Annibali D, Coosemans A, Thomas D, Hermans E, Revents J, Colas E, Vandevijver K, Kruitwagen R, Zikan M, Huvila J, Hayback J, Trovik J, Stukan M, Verheijen R, Massuger L, Mallmann M, Mints M, Moerman P, Amant F

(O2 Muu julkaisu )

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma (2015)

Gynecologic Oncology

Edqvist PHD, Huvila J, Forsstrom B, Talve L, Carpen O, Salvesen HB, Krakstad C, Grenman S, Johannesson H, Ljungqvist O, Uhlen M, Ponten F, Auranen A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. (2013)

Gynecologic Oncology

Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Identifying prognostically relevant subsets of endometrial cancer using unsupervised clustering of immunohistochemical staining data (2013)

Virchows Archiv

Huvila J, Laajala D, Edqvist PH, Talve L, Grenman S, Ponten F, Aittokallio T, Carpen O, Auranen A

(O2 Muu julkaisu )

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)

British Journal of Cancer

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setala M, Harkki P, Jalkanen J, Fraser J, Makinen J, Auranen A, Poutanen M, Perheentupa A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Gene Expression Profiling of Endometrial Adenocarcinomas Reveals Increased Apolipoprotein E Expression in Poorly Differentiated Tumors (2009)

International Journal of Gynecological Cancer

Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsimaki P, Fey V, Kytomaki L, Saukko P, Carpen O, Soini JT, Grenman S, Auranen A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)

British Journal of Cancer

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Contact

Publications

Sort by:

Potential targets analysis reveals pi3k/mtor pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas (2016)

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma (2015)

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. (2013)

Identifying prognostically relevant subsets of endometrial cancer using unsupervised clustering of immunohistochemical staining data (2013)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)

Gene Expression Profiling of Endometrial Adenocarcinomas Reveals Increased Apolipoprotein E Expression in Poorly Differentiated Tumors (2009)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts (2009)